Development and Optimization of Proniosomal Gel Containing Etodolac: In-vitro, Ex-vivo and In-vivo Evaluation

Introduction: Etodolac is used in the treatment of acute pain and inflammation. It has low solubility because high hydrophobicity it reported that upon oral administration shows gastric disturbances. This encourages development topical vesicular formulation.
 Method: In this work we coacervation-phase separation method for etodolac loaded system by using non-ionic surfactants, cholesterol soya lecithin. Central composite design (rotatble) was to optimize concentrations soy lecithin, surfactant cholesterol. The prepared formulations were characterized number vesicles formed, vesicle size, zeta potential, entrapment efficiency, in-vitro permeation, ex-vivo permeation anti-inflammatory study.
 Results: successfully entrapped all having efficiency range 74.36% 90.85%, which more at 4 °C than room temperature. When hydrated with water; niosome 54 141 (per cubic mm) spontaneously produced. results diffusion study revealed released 71.86 97.16% over a period 24 hrs. average size optimized formulation found 211.9 nm PDI 0.5. observed responses i.e. % encapsulation drug release 74.12 95.08 respectively. potential -19.4mV stability further confirmed no changes content after studies. inhibition paw volume 40.52% 43.61% test marketed proniosomal gel.
 Conclusion: Proniosomal gel stable could enhance skin delivery excellent capability system.